Pelvic Cancer Induced Hemorrhegic Cystitis Market

Pelvic Cancer Induced Hemorrhagic Cystitis Market Snapshot (2023 to 2033)

The global Pelvic cancer induced hemorrhagic Cystitis Market size is expected to surpass an impressive valuation of US$ 2.1 Billion in 2023 and is projected to reach US$ 11 Billion by 2033, with a CAGR of 18.01%

Mounting technical breakthroughs allow healthcare organizations to explore innovative services and solutions for managing chronic hemorrhagic Cystitis disorders. Since patients are not required to stay in the hospital for an extended period of time, these breakthroughs decrease costs and patient volume. Furthermore, lowering hospital visits and stays makes this development convenient for older adults. Considering the favorable aspects, many organizations and businesses are developing and implementing the most recent technologies in managing chronic diseases like hemorrhagic cystitis to enhance patient outcomes which will drive market growth.

However, the high costs associated with various devices, strict regulatory policies, poorly developed healthcare infrastructure, and limited adoption of advanced cancer therapies in treating cystitis are restraining the market growth.

2018 to 2022 Pelvic cancer induced hemorrhagic Cystitis Demand Analysis vs. Forecast 2023 to 2033

The Pelvic Cancer Induced Hemorrhagic Cystitis Market was worth around US$ 1.24 Billion in 2018 while growing at a CAGR of 12.7%. The emergence and popularity of targeted therapy.

The rapid strides made in drug targeting techniques have allowed physicians to inject drugs directly into the bladder containing tumors which are aiding in market expansion. Considering these factors, the market is estimated to grow with a CAGR of 18.01%, reaching a valuation of USD 11 billion by end of the forecast period.

Which are Some Prominent Drivers of the Pelvic cancer induced hemorrhagic Cystitis Market?

Strategic Initiatives Adopted by Market Players

Bladder disorders are a number of bladder issues that can affect daily physical activities. The most common bladder disorders are cystitis, interstitial cystitis, overactive bladder, urinary incontinence, and bladder cancer. Most bladder issues are caused by a bacterial infection that enters the urinary tract.

Various strategic initiatives by the market players in terms of collaboration, acquisition, partnership, and others, encourages them to increase their company's product portfolio, leading to market expansion and hence improving the product demand among customers, which ultimately provides the market players to earn maximum revenue. Thus, leading to market growth.

Rising Research and Development Investments and Launch of Novel Therapies in Upcoming Years to Augment Growth

Various treatment options and innovative therapies are available for OAB and other bladder disorders. Many biopharmaceutical and pharmaceutical companies are investing in various unconventional therapies for bladder disorders, which are expected to fuel market expansion.

Combination of Different Target Therapies

Combination Therapies are much more effective than monotherapy, without additional adverse effects. Combination Therapies are a safe and effective alternative for individuals with Cystitis bladder conditions. Combining different target therapy strategies is the best approach to relieving patients of Hemorrhagic Cystitis. Oral medication and behavioral therapy should be considered for the patients' refractory treatment. Various advanced target therapies are available such as sacral neuromodulation, intradetrusor injection of a botulinum toxin A, and percutaneous tibial nerve stimulation. These are advanced treatments and more effective as compared to oral agents which are aiding in market growth.

In addition to this, the growing need for advanced healthcare services, backed by growing concern for the prevalence of chronic diseases amongst individuals is also anticipated to drive the growth of the market. Moreover, the numerous opportunities generated by the surge in the price of medical goods and services in the healthcare industry in various nations are also projected to contribute to the growth of the market during the forecast period.

Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

What are the Challenges Projected to be Faced by the Market?

The challenges in diagnosing the disease and the cost of the treatments and diagnostics are high due to the procedure of various checkpoints along with the high-tech technologies and modalities to perform the procedures.

The cost of the procedure generally gets raised because of the high cost of the advanced technological devices used in the treatment, which is anticipated to restrain the market growth.

Region-Wise Insights

North America to dominate the Haemorrhagic Cystitis Market by 2033

The US held the dominant share in the pelvic cancer-induced hemorrhagic cystitis market in this region. The market in this region is expected to be valued at US$ 900 Million in 2023, and it will reach US$ 3.6 Billion by end of the forecast period while growing at a CAGR of 14.87%. Factors such as the presence of a large target population, rising adoption of novel therapeutics, and multiple product launches are anticipated to boost the growth of the market over the forecast period.

With the increasing burden of bladder and pelvic cancer, the burden of Hemorrhagic Cystitis is also expected to increase. This in turn is likely to increase the demand for its treatment thereby propelling the market growth over the forecast period.

Additionally, several strategies adopted by the key market players are also assisting in market growth. For instance, in June 2020, Pfizer received the United States Food and Drug Administration approval for BAVENCIO. It has been approved as a first-line maintenance treatment among patients suffering from advanced/metastatic urothelial carcinoma. Furthermore, in April 2020, UroGen Pharma received the United States Food and Drug Administration approval for mitomycin gel (Jelmyto), which has been designated for the treatment of low-grade upper tract urothelial cancer. Therefore, increasing approvals from the United States Food and Drug Administration and product launches by key players are anticipated to boost market growth.

Presence of a large targeted population to augment growth in APAC

APAC is anticipated to experience a high growth rate in the hemorrhagic Cystitis treatment drugs market in the next few years due to a rise in Pelvic cancer cases, a growing need for improved bladder cancer treatments and therapies, increasing awareness about cancer diagnosis, an increase in health care expenditure, and developing health care infrastructure in the region. The market in this region will grow at a CAGR of 15.1% and will reach a valuation of USD 3400 million by end of the forecast period.

Growth in pelvic cancer cases, technological advancements, drug innovations regarding the treatment of pelvic cancer, government initiatives, a rise in the aging population, and advanced healthcare services is expected to propel the market for pelvic cancer-induced hemorrhagic cystitis treatment drugs.

China offers strong avenues for market expansion. Factors such as high unmet clinical needs and the presence of a large target population are anticipated to propel the market in this region. Several local players are currently evaluating products as second/third-line treatments in Phase II trials and are well-positioned to be launched in the China market in the upcoming years which will support growth in this region.

Category wise Insights

By treatment type, Chemotherapy to be Most Sought After Treatment

Treatment by Chemotherapy accounts for almost 2/3rd the share in treating hemorrhagic cystitis. Various chemotherapeutic agents, including ifosfamide, cyclophosphamide, busulfan, doxorubicin, dacarbazine, fludarabine, and cabazitaxel, can cause either non-hemorrhagic or hemorrhagic cystitis. The high approval rate of Ifosfamide and cyclophosphamide for use in a variety of malignancies, both in children and adults driving the market for Hemorrhagic Cystitis.

Cyclophosphamide is also used as a component of conditioning regimens prior to hematopoietic cell transplantation and as an immunosuppressant in a variety of rheumatologic (eg, autoimmune disease, vasculitis), nephrology (eg, minimal change nephrotic syndrome), dermatologic (eg, refractory pemphigus), and neurologic (eg, relapsing/remitting multiple sclerosis) conditions.

Radiation therapy acting as a secondary treatment

The radiation therapy for the treatment of Pelvic Cancer induced Hemorrhagic Cystitis Market is expected to account for around 25% segment share by end of the forecast period.

Start-ups in Pelvic Cancer Induced Hemorrhagic Cystitis Treatment Market

• Founded in 2005, ‘Lipella’ is a development-stage biotechnology company based in Pittsburgh, United States. Lipella's products in development target intravesical therapy, which is a method of providing local treatments directly to the urinary bladder lumen via urethral catheterization. Indications targeted include interstitial cystitis (also known as painful bladder syndrome), overactive bladder, and superficial bladder cancer. Lipella products consist of liposome formulations of large multilamellar liposomes made from sphingomyelin lipids which bind to sphingomyelin in the bladder wall, forming a lipid barrier. This protective coating promotes healing and prevents further damage to the bladder wall from urinary toxins. Products in various stages of clinical trials include LP-08 for interstitial cystitis, LP-09 for overactive bladder, and LP-10 for hemorrhagic cystitis. It received a total funding of US$ 3.73 Million.
• Founded in 2004 in Raanana, Israel, ‘UroGen Pharma’ (formerly TheraCoat) is a clinical-stage company focused on the development of therapies for the three types of non-muscle-invasive bladder cancer (NMIBC). Its drug pipeline includes MitoGel (in Phase II/II), a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of upper tract urothelial carcinoma (UTUC); VesiGel (in phase II), a sustained release formulation of a high dose Mitomycin C for low-grade non-muscle invasive bladder cancer (LG-NMIBC); and Vesimune (in Phase II), a new formulation of the TLR7 agonist Imiquimod for local intravesical delivery for the treatment of Carcinoma In-Situ (CIS) (a high-grade NMIBC in the bladder). Imiquimod is a synthetic immune modulator. The company is also developing BotuGel (Phase II), a novel intravesical sustained-release formulation of botulinum toxin for Overactive Bladder (OAB) and Interstitial Cystitis (IC). UroGen Pharma has received orphan drug designations in the US for MitoGel and Vesimune for the treatment of UTUC and CIS, respectively. It received funding of US$ 7 Million from’ RTW investments, ‘Sonostar Ventures’ and ‘Pontifax’.

Market Competition

Key players in Pelvic cancer induced hemorrhagic Cystitis Market are Johnson & Johnson Services, Inc, Astellas Pharma Inc, Eli Lilly and Company, Sanofi, Ipsen Pharma, Bayer AG, AstraZeneca, Valeant Pharmaceuticals International, Inc, Merck & Co., Inc., Pfizer Inc.

• In April 2022, Pfizer made an equity investment worth US$ 25 Million in Zentalis Pharmaceuticals, Inc. This investment is expected to help Pfizer to leverage its development capabilities globally
• In May 2022, Pfizer entered a research collaboration agreement of two years with NetVation DL Medicine. This collaboration is anticipated to aid and advance Pfizer in its research activities
• In June 2022, Roche introduced a human papillomavirus (HPV) self-sampling solution that enables patients to perform HPV screening in the presence of a healthcare worker. This is expected to expand the company’s cancer screening solution line-up
• In June 2022, Valencia Technologies Corporation announced the implantable neuromodulation technology product eCoin®, which is reshaping the delivery of long-term therapy for bladder control, is a tibial implant for Urge Urinary Incontinence (UUI). eCoin® received premarket approval (PMA) from the US Food and Drug Administration (FDA) in March 2022, making it the first and only FDA-approved implantable tibial neurostimulator indicated for the treatment of urge urinary incontinence (UUI). This new product has helped the company to increase its portfolio

Report Scope

Key Segments Profiled in the Pelvic Cancer Induced Hemorrhagic Cystitis Market Industry Survey

By Treatment:

• Bone Marrow Transplant
• Chemotherapy
  • Cyclophosphamide
  • Ifosfamide
• Radiation Therapy
• Other Treatments

By Region:

• North America
• Latin America
• Europe
• Asia Pacific
• Middle East & Africa (MEA)